CoChat

Phase II study of avelumab in multiple relapsed/refractory germ cell cancer

Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., Mardiak, J. · 2019 · Investigational New Drugs

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background Germ cell tumors (GCTs) are highly curable diseases; however, not all patients can be cured. Patients in their second relapse have especially poor prognoses. PD-L1 expression is significantly higher in GCTs than in normal testicular tissue, and high PD-L1 expression is associated with a poor prognosis. This study aimed to determine the efficacy and safety of avelumab, a PD-L1 inhibitor, in patients with GCTs. Methods In this phase 2 study, patients with multiple relapsed and/or refractory GCTs were treated with avelumab at a dose of 10 mg/kg administered biweekly until progression or unacceptable toxicity. The primary endpoint was 12-week progression-free survival (PFS). Fifteen evaluable patients had to be enrolled in the first cohort, and if <8 of 15 patients had 12-week PFS, the study was to be terminated. Here, we report the results of the first stage of the trial. Results From November 2017 to January 2018, 8 patients with a median age of 29 years (range, 22 to 52 months) were enrolled. Patients were pretreated with a median of 5 (range, 1 to 6) previous lines of platinum-based therapies; 5 tumors (62.5%) were absolutely refractory to cisplatin, and 5 patients (62.5%) had visceral nonpulmonary metastases. At a median follow-up period of 2.6 months (range, 0.3 to 14.4), all the patients experienced disease progression, and 7 patients (87.5%) died. The twelve-week PFS was 0%, median PFS was 0.9 months (95% CI 0.5-1.9), and median OS was 2.7 months (95% CI 1.0-3.…

Overview

Integrity signals

Registry

Crossref · 10.1007/s10637-019-00805-4

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 83

Metadata

Authors
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J.
Affiliations
Comenius University Bratislava (SK)
Corresponding author
Mego, M.
Venue
Investigational New Drugs
Published
2019-06-01
Volume
37
Issue
4
Pages
748-754
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2947584913
Cited by
81
References
32
Citations by year
2026: 7 · 2025: 9 · 2024: 16 · 2023: 8 · 2022: 10 · 2021: 17 · 2020: 12 · 2019: 2
FWCI
9.78
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Investigational New Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
Vedecká grantová agentúra MS SR (VEGA 1/0174/19, VEGA 1/0043/18)
Topics
  • Health Sciences › Medicine › Surgery › Testicular diseases and treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
avelumab, germ cell tumors, PD-L1 inhibitors, PD-L1 expression, progression-free survival, treatment efficacy, drug safety, platinum-refractory disease, metastatic germ cell tumors
MeSH terms
Progression-Free Survival, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Germ Cell and Embryonal, Drug Resistance, Neoplasm, Young Adult, B7-H1 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of avelumab in multiple relapsed/refractory germ cell cancer. https://app.cochat.ai/papers/10.1007/s10637-019-00805-4
The paper
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J. (2019). Phase II study of avelumab in multiple relapsed/refractory germ cell cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-019-00805-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.